These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 3532900

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J, Rovenský J, Tauchmannová H, Zitnan D.
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [Abstract] [Full Text] [Related]

  • 3. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA, Mellinger S, Kohler J, Dorsey JK, Furst DE.
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [Abstract] [Full Text] [Related]

  • 4. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [Abstract] [Full Text] [Related]

  • 5. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B, Elmér O, Akesson A.
    Int Angiol; 1988 Apr; 7(1):19-25. PubMed ID: 3290356
    [Abstract] [Full Text] [Related]

  • 6. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ, Wijn PF, van Lier HJ, Skotnicki SH.
    Int Angiol; 1987 Apr; 6(3):313-22. PubMed ID: 3329207
    [Abstract] [Full Text] [Related]

  • 7. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ, Wijn PF, van Lier HJ, Skotnicki SH.
    Microcirc Endothelium Lymphatics; 1985 Apr; 2(6):657-85. PubMed ID: 2942753
    [Abstract] [Full Text] [Related]

  • 8. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS, Gilgor RS, Allen LM, Duvic M.
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [Abstract] [Full Text] [Related]

  • 9. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M.
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A, McCans J, Willan AR, Ford PM.
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [Abstract] [Full Text] [Related]

  • 12. [Calcium antagonists for the treatment of Raynaud's phenomenon].
    Müller-Bühl U, Diehm C, Scheuermann W, Mörl H.
    Dtsch Med Wochenschr; 1983 Nov 25; 108(47):1795-7. PubMed ID: 6357692
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Slow release nifedipine in the treatment of Raynaud's phenomenon.
    Costantini A, Martelli E, Bavera P, Agus GB.
    Int Angiol; 1987 Nov 25; 6(4):359-63. PubMed ID: 3330116
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.
    Rustin MH, Grimes SM, Kovacs IB, Cooke ED, Bowcock SA, Sowemimo-Coker SO, Turner P, Kirby JD.
    Eur J Clin Pharmacol; 1984 Nov 25; 27(1):61-5. PubMed ID: 6386490
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S, Wigley FM.
    Curr Opin Rheumatol; 2007 Nov 25; 19(6):611-8. PubMed ID: 17917543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.